Douglas J Watson
Overview
Explore the profile of Douglas J Watson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cui Y, Watson D, Girman C, Shapiro D, Gotto A, Hiserote P, et al.
Am J Cardiol
. 2009 Sep;
104(6):829-34.
PMID: 19733719
Reducing low-density lipoprotein (LDL) cholesterol with statins reduces cardiovascular risk, but the associations between increases in high-density lipoprotein (HDL) cholesterol and cardiovascular risk at different LDL levels have been less...
12.
Schlesinger N, Norquist J, Watson D
J Rheumatol
. 2009 Apr;
36(6):1287-9.
PMID: 19369457
Objective: To study the frequency of normal serum urate (SU) levels during acute gout in the largest studies of acute gout treatment to date. Methods: Data collected from 2 randomized...
13.
Kamal-Bahl S, Watson D, Ambegaonkar B
Clin Ther
. 2009 Feb;
31(1):130-40.
PMID: 19243714
Background: Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing. Objective: The objective of this study was to determine the...
14.
Kamal-Bahl S, Burke T, Watson D, Wentworth C
Curr Med Res Opin
. 2008 May;
24(6):1817-21.
PMID: 18485268
Objective: To examine the dosage, titration patterns, and gaps in treatment of newly-initiated ER niacin in clinical practice. Research Design And Methods: Historical cohort study using the Ingenix Lab/Rx database....
15.
Avins A, Manos M, Ackerson L, Zhao W, Murphy R, Levin T, et al.
Drug Saf
. 2008 Mar;
31(4):325-34.
PMID: 18366243
Background: Little is known about the potential adverse hepatic effects of HMG-CoA reductase inhibitors ('statins') in patients with existing liver disease; therefore, we examined the risk of liver toxicity with...
16.
Paolini J, Mitchel Y, Reyes R, Kher U, Lai E, Watson D, et al.
Am J Cardiol
. 2008 Mar;
101(5):625-30.
PMID: 18308010
Niacin (nicotinic acid) is not optimally used mainly because of flushing, a process mediated primarily by prostaglandin D(2), which leads to poor patient compliance and suboptimal dosing. This phase II...
17.
Morrison A, Ramey D, van Adelsberg J, Watson D
Curr Med Res Opin
. 2007 Aug;
23(10):2395-404.
PMID: 17714606
Objective: To investigate the effects of continued use of non-selective NSAIDs (nsNSAIDs) on blood pressure and hypertension. Research Design And Methods: This was a systematic review of randomized clinical trials...
18.
Norquist J, Watson D, Yu Q, Paolini J, McQuarrie K, Santanello N
Curr Med Res Opin
. 2007 Jun;
23(7):1549-60.
PMID: 17559750
Background: Niacin is currently the most effective approved agent for raising high-density lipoprotein cholesterol. However, niacin-induced cutaneous flushing (redness, warmth, tingling and/or itching) significantly limits patient acceptance. To further characterize...
19.
Watson D, Rahme E, Santanello N
Drug Saf
. 2006 Dec;
30(1):89-90.
PMID: 17194174
No abstract available.
20.
Rahme E, Watson D, Kong S, Toubouti Y, LeLorier J
Pharmacoepidemiol Drug Saf
. 2006 Nov;
16(5):493-503.
PMID: 17086567
Purpose: To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population. Methods: We conducted a retrospective...